SHINGLES TREATMENT MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Shingles Treatment Market Size and Forecast – 2025 to 2032

The Global Shingles Treatment Market is estimated to be valued at USD 124.11 Bn in 2025 and is expected to reach USD 234.26 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 9.5% from 2025 to 2032. The significant growth of the global shingles treatment market is driven by increasing awareness about the risks and complications of shingles, particularly in older adults. This includes greater understanding of the importance of prevention through vaccines like Shingrix, which are effective in reducing the incidence of the disease.

Key Takeaways of the Global Shingles Treatment Market

• In the global shingles treatment market, the vaccines (prophylactic) segment is expected to lead with the largest market share of 74.3% in 2025.
• Among the different routes of administration, the oral segment will hold the largest share, accounting for an estimated 45.6% in 2025.
• Additionally, the adults (50-64 years) segment is projected to dominate the market, representing 80.5% of the total market share in 2025.
• North America is expected to lead the market, holding a share of 39.3% in 2025.
• Asia Pacific is anticipated to be the fastest-growing region, with an estimated market share of 24.5% in 2025.

Market Overview

Market trends indicate a strong shift towards innovative therapeutic solutions, including targeted antiviral drugs and vaccine developments that enhance patient outcomes. Additionally, the rising geriatric population and increasing healthcare expenditure globally are fueling the demand for effective shingles treatments. The integration of digital health technologies for early diagnosis and personalized treatment plans is also gaining traction, making the market dynamic and competitive with enhanced patient-centric approaches.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Download Free Sample

Shingles Treatment Market Insights, By Treatment Type - Dominance of Vaccines (Prophylactic) in Treatment Type is Driven by Preventive Healthcare Focus

The vaccines (prophylactic) segment is expected to hold the largest market share of 74.3% in the global shingles treatment market in 2025, primarily driven by the increasing focus on preventive health management. Vaccines, in particular, the Recombinant Zoster Vaccine (RZV) and Live Attenuated Zoster Vaccine (ZVL), have transformed shingles management because of the change in the paradigm of management towards proactive prevention instead of reactive management.

In February 2023, Pfizer and BioNTech initiated a Phase 1/2 trial for their mRNA-based shingles vaccine. The trial will enroll up to 900 U.S. volunteers aged 50–69 to assess safety, tolerability, and immunogenicity. The companies aim to develop a high-efficacy, well-tolerated, and globally efficient vaccine. The vaccine, utilizing Pfizer's antigen technology and BioNTech's mRNA platform, targets glycoprotein E (gE) on the varicella zoster virus. Shingles, a painful rash caused by the virus, affects millions worldwide.

Shingles Treatment Market Insights, By Route of Administration - Oral Route of Administration Leads Through Patient Convenience and Treatment Compliance

The oral segment is projected to account for the largest share of 45.6% in 2025, as it is a preferred method of shingles treatment administration due to its patient convenience and clinical effectiveness. The ease of use and convenience of oral medications play a crucial role in enhancing patient adherence to therapy, making it a key factor in the treatment of shingles.

Acyclovir, Valacyclovir, and Famciclovir are antiviral drugs that are mostly administered orally and they act systemically by preventing viral replication in the initial stages of the disease. Oral route is also more patient compliant because the administration can be done at home since it does not involve a visit to the clinic and other special skills like in the case of parenteral injections.

Shingles Treatment Market Insights, By Age Group - Higher Impact on Adults (50-64 Years) is Fueled by Rising Health Awareness and Early Intervention

The adults (50-64 years) age group is expected to account for 80.5% of the global shingles treatment market in 2025 as it is largely influenced by demographic, behavioral, and clinical factors. This age group, typically older adults, is more susceptible to shingles, which drives higher awareness of healthcare and the importance of early disease prevention. Their increased focus on maintaining health and preventing illnesses contributes to the dominant share of this segment.

The 50-64 group, in contrast to the aged (65 years and above), may still be actively involved in the labor force and still have more interaction with healthcare services. Frequent screening and check-ups establish additional chances of evaluating the risk of shingles and early management.

Vaccination Coverage and Unmet Gap Analysis for Shingles Treatment by Country

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Regional Insights

To learn more about this report, Download Free Sample

North America Shingles Treatment Market Analysis and Trends

In North America, the shingles treatment market is projected to hold 39.3% share of the market, driven by robust healthcare infrastructure, significant healthcare spending, and advanced research capabilities. These factors contribute to the region's dominance in the market, with strong investments in both treatment options and ongoing medical research. The existence of major pharmaceutical and biotechnology firms that have invested heavily in research and development has seen the emergence of new shingles treatment and vaccines. The adoption of shingles therapies is supported by government policies such as strong healthcare insurance cover and antiviral drugs support.

In November 2021, GlaxoSmithKline Inc., a global healthcare company, announced that SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted) was approved in Canada for adults aged 18 and older at increased risk of shingles due to immunodeficiency or immunosuppression.

Asia Pacific Shingles Treatment Market Analysis and Trends

The shingles treatment market in Asia Pacific has the highest growth rate due to the growing access to healthcare with an estimated 24.5% share in 2025. This growth is driven by growing awareness about the complication of shingles and the expanding healthcare infrastructure in the new emerging economies of China and India. Multinational pharmaceutical companies are becoming increasingly active in terms of setting up manufacturing bases or forming alliances with local companies in the market ecosystem.

Companies such as GlaxoSmithKline and Sanofi are paying more attention to the clinical trials and vaccine distribution in this area. Trade dynamics, such as improvements in import-export policies and regional free trade agreements, can facilitate smoother supply chain operations.

Global Shingles Treatment Market Outlook for Key Countries

U.S. Shingles Treatment Market Trends

The U.S. continues to lead the shingles treatment market, driven by its strong healthcare infrastructure and significant financial investments in research and development by major pharmaceutical companies. The approval and the overall adoption of vaccines, such as Shingrix, has greatly influenced the outcomes of patients. The U.S. FDA helps speed up the approval of new treatments for shingles by the government, and Medicare and private insurance facilitate the access of older adults to vaccines. The key stakeholders such as Pfizer and Merck are also taking an active part by engaging in clinical innovations and educating the patient to raise awareness, thereby stimulating the growth of the market.

In January 2025, Curevo Vaccine announced positive Phase 2 data for its shingles vaccine, Amezosvatein (CRV-101). The vaccine showed non-inferior immune response to Shingrix one year after the second dose, with no confirmed shingles cases in the highest antigen dose group. Amezosvatein’s better tolerability compared to Shingrix positions it as a promising alternative in the USD 5 billion shingles vaccine treatment market. Curevo plans to continue development, aiming for significant market share.

Germany Shingles Treatment Market Trends

The market of shingles treatment in Germany is associated with a well-developed healthcare system and supportive conditions that support shingles management in the country. Healthcare policies in the country encourage vaccination initiatives mostly among the elderly population, encouraging schemes of public reimbursements. Bayer and BioNTech are the top companies that are involved in research and collaboration on the vaccine enhancement and antiviral therapy research. The strategic positioning of Germany in Europe also makes cross-border trade and competition in the regional market easier.

Bayer and BioNTech are key players, focusing on vaccine innovation and antiviral therapies. Germany’s national healthcare policies support vaccine accessibility, especially for the elderly, boosting market development.

China Shingles Treatment Market Trends

The shingles treatment market in China is growing rapidly, fueled by increased investments in healthcare infrastructure and a rising awareness among the population. Government efforts are focused on increasing access to vaccines and antivirals both in urban and rural areas. Multinationals like GlaxoSmithKline and local companies like Sinovac are increasing the frequency of clinical research and product releases for the local population. The changing regulatory environment will help speed up drug approvals, and, along with increasing earnings and ageing population, the market potential will be increased dramatically.

GlaxoSmithKline (GSK) and Sinovac are expanding the China shingles treatment market. GSK’s Shingrix and Sinovac’s antiviral treatments are supported by government programs to increase vaccine access, particularly for the aging population.

Japan Shingles Treatment Market Trends

The Japan shingles treatment market has a developed healthcare ecosystem and an aging population, which encourages the demand of preventive and curative solutions. The Japanese government has also come up with health policies that have emphasized on immunization programs in old care centers. Companies, such as Daiichi Sankyo and Takeda, have key roles in the development of vaccines and the distribution of antivirals. The focus of Japan on digital health technology integration is also beneficial in educating patients and adhering to treatment, which improves the overall market dynamics.

In Japan, Daiichi Sankyo and Takeda lead in vaccine development and antiviral treatments. Government policies promote immunization for the elderly, and digital health integration enhances patient education and treatment adherence.

End User Feedback and Unmet Needs - Global Shingles Treatment Market

• End users in the global shingles treatment market have highlighted both satisfaction and challenges. Positive feedback often focuses on the effectiveness of the Shingrix vaccine, with healthcare professionals noting its high efficacy in preventing shingles and postherpetic neuralgia (PHN), especially in older adults. However, a common concern is the cost of treatments, which can be prohibitive, particularly in regions with limited insurance coverage, causing delays in care.
• Key unmet needs include the lack of personalized treatment options for specific patient groups, such as the immunocompromised, and ongoing access issues in lower-income regions. Addressing these gaps by making treatments more affordable and accessible could open growth opportunities, improve patient outcomes, and inspire innovation in the market.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Download Free Sample

Key Developments

• In November 2025, researchers from Imperial College London and Imperial College Healthcare NHS Trust, funded by GlaxoSmithKline (GSK), launched a clinical trial to explore whether temporarily pausing JAK inhibitor (JAK-i) therapy in patients with inflammatory bowel disease (IBD) can improve immune responses to the Shingrix vaccine. The trial, involving 268 participants, will assess whether a short-term pause can safely boost immune responses to the vaccine without worsening IBD.
• In November 2025, the UAE Ministry of Health and Prevention (MoHAP) launched a national shingles vaccination campaign. The Shingrix vaccine, now available in healthcare facilities across all seven emirates, targets adults aged 50 and above. The vaccine, administered in two doses, helps prevent shingles and its complications like Postherpetic Neuralgia (PHN). Residents aged 18 and older with weakened immune systems are also encouraged to get vaccinated.
• In October 2025, Dynavax Technologies presented promising results from its phase 1/2 trial for Z-1018, a new shingles vaccine. The trial showed strong immune responses and good tolerability. Dynavax also launched a head-to-head study comparing Z-1018 with Shingrix in adults aged 70 and older. The vaccine, a non-live recombinant subunit, combines glycoprotein E with CpG 1018 and alum.
• In April 2023, GSK plc. launched Shingrix in India to prevent shingles in adults over 50. Shingrix, a non-live recombinant vaccine, offers over 90% efficacy and provides at least 10 years of protection. The vaccine targets the varicella zoster virus, which causes shingles. Adults with chronic conditions like diabetes or heart disease are at higher risk.

Top Strategies Followed by Global Shingles Treatment Market Players

• Established players in the market are characterized by large investment in research and development (R&D) and, accordingly, the constant innovation in the high-performance shingles treatment products. These companies are more concerned about creating better formulations which achieve better durability, weather resistance and are friendlier to the environment, satisfying changing market needs and regulations.
  • GSK (GlaxoSmithKline) invests heavily in R&D, with treatments like Shingrix, a recombinant zoster vaccine. It provides enhanced protection against shingles, offering superior efficacy and durability, meeting both market and regulatory demands.

• Mid-level players in the market of shingles treatment are rather cost-conscious and concentrate their efforts on providing cost-efficient solutions that will create a balance between the product and its price. These firms are aware of the huge market potential of price sensitive buyers such as residential contractors and small scale builders who do not have to pay high prices to have quality products.
  • Merck offers cost-effective antiviral treatments like Zovirax (Acyclovir), which balances affordability and effectiveness for patients with shingles. These products cater to price-sensitive consumers, including small healthcare providers.

• The small players in the international market of shingles treatment across the world have a very specialized and innovative way of making an impression in an otherwise crowded market. Such companies are usually interested in niche markets, where they come up with variants of their products that make them unique like eco-friendly methods, fast-drying formulas, or climate specific formulas.
  • Vical Inc. focuses on niche shingles treatments like Vaxfectin, an adjuvant designed to enhance the immune response in shingles vaccines. They target specific markets with highly specialized and innovative approaches to differentiate themselves.

Market Report Scope

Shingles Treatment Market Report Coverage

Shingles Treatment Market Dynamics

To learn more about this report, Download Free Sample

Shingles Treatment Market Driver - Increased Awareness of Shingles Complications

The increasing knowledge about the high-rate complications of shingles including postherpetic neuralgia (PHN), loss of sight, and neurological conditions are majorly affecting the demand of effective treatments of shingles around the globe. With increased knowledge about the sustained pain and potential long-term effects associated with untreated or poorly controlled infections of shingles by the healthcare provider and patients, the focus now shifts to prescriptions and timely treatment.

It is this increasing awareness that is driving people particularly in those age groups who are more prone to shingles to seek preventive strategies, antiviral treatments and pain relief treatment to reduce the risk of complications. Besides, social education and awareness campaigns are strengthening the knowledge that shingles is no longer a painful rash, but a disease that may cause incapacitating health complications unless dealt with adequately.

In February 2024, the International Federation on Ageing (IFA) launched the Shingles Awareness Week Campaign in Canada. Running from February 26 to March 6, the campaign aims to raise awareness about shingles, a preventable disease that primarily affects adults over 50. Despite the availability of effective vaccination, awareness and vaccination rates remain low. The campaign includes a podcast with Dr. Samir Sinha, videos, and resources for civil society organizations

Shingles Treatment Market Opportunity - Expansion of Immunization Programs and Government Vaccination Drives in High-Risk Populations

The global shingles treatment market will be in a good position to enjoy the growth of immunization programs and the vaccination campaigns conducted by the government among high-risk population groups. Older adults and immunocompromised persons are the main target of preventive healthcare programs as they are the major sufferers of shingles.

The world governments are paying increased attention to the cost of shingles complication to the health systems of the population in the form of post herpetic neuralgia and introducing shingles vaccination into national immunization programs. Optimized funding and policy encouraging adult vaccination strategies in the aging areas of the world such as North America, Europe, and some parts of Asia Pacific offer a solid framework that leads to the adoption of vaccines.

In July 2025, NHS England announced that starting September 1, 2025, the eligibility for the Shingrix shingles vaccine will expand to include all severely immunosuppressed individuals aged 18 and over. This update follows advice from the Joint Committee on Vaccination and Immunisation (JCVI). Previously, only those aged 50 and over were eligible. The vaccine, administered in two doses, will be offered to individuals with severe immunosuppression, including those on immunosuppressive therapy. Those who received Zostavax prior to immunosuppression will be offered two doses of Shingrix.

Analyst Opinion (Expert Opinion)

• The shingles treatment market is expanding fast because of the innovation in vaccine technology and the rising trend in creating awareness about the long-term impacts of the disease like the post-herpetic neuralgia. Key drivers are regulatory assistance, including the incorporation of Shingrix in national immunization campaigns, and the growing ageing population around the world. Nevertheless, issues such as low rates of vaccination in certain areas and high prices of vaccines still affect the development of the market.
• Expanding vaccine access in developing countries has been supported by government efforts, such as the launch of Shingrix in India and the expansion of access to immunosuppressed individuals in the U.S. International symposia, including the International Society of Vaccines Congress, have played a crucial role in sharing knowledge, leading to partnerships and policy enhancements that are expected to continue driving growth in the shingles treatment market.

Market Segmentation

• Treatment Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Vaccines (Prophylactic)
    • Recombinant Zoster Vaccine (RZV)
    • Live Attenuated Zoster Vaccine (ZVL)
  • Antiviral Medications
    • Acyclovir
    • Valacyclovir
    • Famciclovir
  • Pain Management
    • Capsaicin
    • Lidocaine
    • NSAIDs
    • Opioids
  • Adjuvant Analgesics
    • Anticonvulsants (e.g., Gabapentin, Pregabalin)
    • Tricyclic Antidepressants (e.g., Amitriptyline)
• Route Of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Topical
  • Parenteral
• Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Adults (50-64 years)
  • Older Adults (≥65 years)
• Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Prescription (antivirals, neuropathic‑pain drugs, vaccines)
  • Over‑the‑counter (topical creams, analgesics)
• End User Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Others
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi
  • Novartis AG
  • Teva Pharmaceutical Industries Ltd.
  • Abbott Laboratories
  • Cipla Limited
  • Camber Pharmaceuticals
  • Eli Lilly and Company
  • Johnson & Johnson
  • AstraZeneca
  • Vi­atris Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Reddy’s Laboratories Ltd.

Sources

Primary Research Interviews

• Industry Stakeholders
  • Hospital dermatology departments
  • Immunization program managers
• End Users
  • Shingles patients
  • Caregivers of shingles patients

Government and International Databases

• CDC (Shingles data)
• National health registries
• WHO (global immunization data)
• Public health surveillance databases
• Global burden of disease data
• Health Technology Assessments (e.g., HIQA)

Trade Publications

• Health Technology Assessment reports
• Public health advisories on shingles
• Risk-factor meta-analyses
• Government health bulletins
• Public hospital reports
• Reports on vaccine cost-effectiveness

Academic Journals

• Frontiers in Medicine
• International Journal of Dermatology
• Systematic reviews on herpes zoster
• Cohort studies on risk factors
• Clinical trials on shingles treatments
• Journal of Infectious Diseases

Reputable Newspapers

• National health news sections
• Global health news outlets
• Public-interest articles on shingles

Industry Associations

• National immunization committees
• Dermatology associations
• Public health associations
• Patient advocacy groups
• Global vaccine alliances
• Hospital associations

Public Domain Resources

• NCBI Bookshelf
• Public-access systematic reviews
• Open-access health tech assessments
• Government health portals (CDC)
• Open epidemiological datasets
• Public health models from HTAs

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years